

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24751-2502SERIAL NO.  
09/846,637LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Jensen, Michael C.FILING DATE  
April 30, 2001GROUP  
1632RECEIVED  
OCT 15 2002  
TECH CENTER 1600/2800

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
48	A	3	6	5	5	5	9	9	04/11/72	Kay and Beckman	260	23.7	05/18/70
	B	4	0	8	7	5	3	5	05/02/78	Heubach	424	272	06/03/76
	C	4	3	5	1	8	4	1	09/28/82	Kammerer <i>et al.</i>	424	272	03/03/81
	D	4	4	3	0	8	9	1	02/14/84	Holm	72	149	12/31/84
	E	4	5	3	0	8	4	5	07/23/85	Ikushima <i>et al.</i>	514	453	07/6/83
	F	4	6	8	0	2	9	9	07/14/87	Hesson	514	311	04/26/85
	G	4	6	8	6	2	3	4	08/11/87	Nelson <i>et al.</i>	514	469	11/27/85
	H	4	7	2	5	6	2	2	02/16/88	Nelson <i>et al.</i>	514	469	01/23/86
	I	4	7	2	7	0	6	9	02/23/88	Nelson <i>et al.</i>	514	211	01/30/87
	J	4	7	4	8	1	7	3	05/31/88	Nelson <i>et al.</i>	514	211	09/23/87
	K	4	7	5	3	9	3	5	06/28/88	Nelson <i>et al.</i>	514	233.5	01/30/87
	L	4	7	8	6	6	3	7	11/22/88	Allison <i>et al.</i>	514	233.5	01/22/88
	M	4	8	0	8	5	9	2	02/28/89	Nelson <i>et al.</i>	514	233.5	09/04/87
	N	4	8	6	1	7	7	6	08/29/89	Nelson <i>et al.</i>	514	233.5	02/25/88
	O	4	8	6	1	7	8	3	08/29/89	Ackerman <i>et al.</i>	514	311	04/26/88
	P	4	8	6	8	1	5	3	09/19/89	Allison <i>et al.</i>	514	470	08/17/88
	Q	4	9	2	2	4	6	7	05/01/90	Caulfield	367	87	03/23/89
	R	4	9	4	8	7	9	3	08/14/90	Allison <i>et al.</i>	514	233.5	06/29/89
	S	4	9	5	2	5	7	9	08/28/90	Nelson <i>et al.</i>	514	233.5	11/14/88
	T	4	9	5	9	3	8	7	09/25/90	Nelson <i>et al.</i>	524	469	11/24/87
	U	4	9	6	5	2	7	6	10/23/90	Bartlett <i>et al.</i>	514	378	09/25/86
	V	4	9	6	8	7	0	1	11/06/90	Ackerman <i>et al.</i>	514	312	04/26/88
	W	4	9	9	2	4	6	7	02/12/91	Allison <i>et al.</i>	514	464	03/28/90
48	X	5	0	3	2	5	9	7	07/16/91	Hesson	514	311	03/26/87

EXAMINER

DATE CONSIDERED

2.20.03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24751-2502SERIAL NO.  
09/846,637LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Jensen, Michael C.FILING DATE  
April 30, 2001GROUP  
1632

TECH CENTER 1600/1500

OCT 15 2002

RECEIVED

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
YJ	Y	5	0	8	4	4	6	2	01/28/92	Ackerman <i>et al.</i>	514	311	06/28/90
	Z	5	2	4	7	0	8	3	09/21/93	Knox <i>et al.</i>	544	153	12/18/92
	AA	5	3	1	4	8	0	5	05/24/94	Haugland <i>et al.</i>	435	29	10/28/91
	AB	5	3	8	0	8	7	9	01/10/95	Sjogren	549	310	02/18/94
	AC	5	3	9	6	7	6	7	03/14/95	Suzuki	60	298	02/08/93
	AD	5	4	1	1	8	7	2	05/02/95	Rajasekaran	435	30	09/08/93
	AE	5	4	4	4	0	7	2	08/22/95	Patterson <i>et al.</i>	514	320	02/18/94
	AF	5	4	6	2	9	2	9	10/31/95	Kawashima <i>et al.</i>	514	43	08/03/92
	AG	5	5	6	9	6	5	0	10/29/96	Watanabe <i>et al.</i>	514	43	06/11/93
	AH	5	6	2	4	9	4	6	04/29/97	Williams	514	378	07/05/94
	AI	5	6	5	8	8	9	0	08/19/97	Pankiewicz <i>et al.</i>	514	43	03/30/95
	AJ	5	6	6	5	3	5	0	09/09/97	Quesenberry	424	93.21	11/23/94
	AK	5	6	8	8	8	2	4	11/18/97	Williams	514	378	02/07/96
	AL	5	7	0	0	7	8	6	12/23/97	Watanabe <i>et al.</i>	514	47	06/07/95
	AM	5	8	0	7	8	7	6	09/15/98	Armistead <i>et al.</i>	514	374	04/23/96
	AN	5	8	3	4	2	5	6	11/10/98	Finer <i>et al.</i>	435	91.33	06/11/93
	AO	5	8	3	4	4	4	0	11/10/98	Goldenberg <i>et al.</i>	514	44	09/12/95
	AP	5	9	0	5	0	9	0	05/18/99	Bertolini <i>et al.</i>	514	522	04/29/98
	AQ	5	9	2	8	6	3	8	07/27/99	Uchida <i>et al.</i>	424	93.21	06/17/96
	AR	5	9	3	2	6	0	0	08/03/99	Saunders <i>et al.</i>	514	365	03/14/97
	AS	5	9	9	3	8	0	1	11/30/99	Greenberger <i>et al.</i>	424	93.21	08/19/97
	AT	6	0	0	8	0	3	5	12/28/99	Johnston <i>et al.</i>	435	235.1	06/22/98
	AU	6	0	2	5	1	9	2	02/15/00	Beach <i>et al.</i>	435	320.1	09/20/96
YJ	AV	6	0	5	4	4	7	2	04/25/00	Armistead <i>et al.</i>	514	374	04/02/97

EXAMINER

YJ

DATE CONSIDERED

2-20-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24751-2502SERIAL NO.  
09/846,637LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Jensen, Michael C.FILING DATE  
April 30, 2001GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
<i>JS</i>	AW	6	0	6	3	8	9	3	05/16/00	Gordon <i>et al.</i>	435	69.1	11/12/96
	AX	6	0	6	8	8	3	6	05/30/00	Quesenberry	424	93.21	11/22/95
<i>JS</i>	AY	6	1	2	8	5	8	2	10/03/00	Wilson <i>et al.</i>	702	27	04/30/96

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
<i>JS</i>	AZ	0	0	2	5	7	8	0	05/11/00	PCT				
	BA	0	0	2	6	1	9	7	05/11/00	PCT				
	BB	0	0	4	4	3	8	8	08/03/00	PCT				
	BC	9	1	0	2	8	0	5	03/07/91	PCT				
	BD	9	1	0	6	8	6	3	05/16/91	PCT				
	BE	9	4	0	1	1	0	5	01/20/94	PCT				
	BF	9	4	1	2	1	8	4	06/09/94	PCT				
	BG	9	6	0	1	1	1	1	01/18/96	PCT				
	BH	9	6	1	4	8	6	5	05/23/96	PCT				
	BI	9	6	3	3	2	8	1	10/24/96	PCT				
	BJ	9	6	3	3	2	8	2	10/24/96	PCT				
	BK	9	7	4	0	0	2	8	10/30/97	PCT				
	BL	9	7	4	5	1	4	2	12/04/97	PCT				
	BM	9	7	4	5	1	4	5	12/04/97	PCT				
	BN	9	8	1	3	0	4	7	04/02/98	PCT				
	BO	9	8	4	0	3	8	1	09/17/98	PCT				
	BP	9	9	3	3	9	9	6	07/08/99	PCT				
<i>JS</i>	BQ	9	9	5	5	6	6	3	11/04/99	PCT				

EXAMINER

*Ymk*DATE CONSIDERED *2-20-03*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**

FORM PTO-1449 (Modified)  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 24751-2502	SERIAL NO. 09/846,637
	APPLICANT Jensen, Michael C.	
	FILING DATE April 30, 2001	GROUP 1632

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

y	BR	"Gene Therapy Approach for Chronic Granulomatous Disease," <i>NIH Clinical Research Studies</i> , Protocol Number: 95-I-0134, <a href="http://clinicalstudies.info.nih.gov/detail/B_1995-I-0134.html">http://clinicalstudies.info.nih.gov/detail/B_1995-I-0134.html</a> (09/05/02)
	BS	"HLA-Matched, Peripheral Blood Stem Cell Transplantation Using Low Intensity Conditioning to Treat Patients with Chronic Granulomatous Disease Who Are Actively Infected," <i>NIH Clinical Research Studies</i> , Protocol Number: 01-I-0013, <a href="http://clinicalstudies.info.nih.gov/detail/A_2001-I-0013.html">http://clinicalstudies.info.nih.gov/detail/A_2001-I-0013.html</a> (09/05/02)
	BT	<del>Adams et al., "The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice", <i>Nature</i>, 318:533-538 (1985)</del>
	BU	Agarwal et al., "Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis", <i>J. Clin. Invest.</i> , 106(2):245-252 (2000)
	BV	Aksentijevich et al., "In Vitro and In Vivo Liposome-Mediated Gene Transfer Leads to Human MDR1 Expression in Mouse Bone Marrow Progenitor Cells", <i>Hum. Gen. Ther.</i> , 7:1111-1122 (1996)
	BW	Albrecht et al., "Cationic lipid mediated transfer of c-abl and bcr antisense oligonucleotides to immature normal myeloid cells: Uptake, biological effects and modulation of gene expression", <i>Ann. Hematol.</i> , 72:73-79 (1996)
	BX	Alexander et al., "Expression of the c-myc Oncogene under Control of an Immunoglobulin Enhancer in Eμ-myc Transgenic Mice", <i>Mol. Cell Biol.</i> , 7(4):1436-1444 (1987)
	BY	Allison and Eugui, "Immunosuppressive and other effects of mycophenolic acid and an ester prodrug mycophenolate mofetil," <i>Immunological Reviews</i> , 136: 5-27 (1993)
	BZ	Allison and Eugui, "Mycophenolate mofetil and its mechanisms of action," <i>Immunopharmacology</i> , 47: 85-118 (2000)
	CA	Allison and Eugui, "The design and development of an immunosuppressive drug, mycophenolate mofetil," <i>Springer Seminars in Immunopathology</i> , 14: 353-380 (1993)
	CB	Allison et al., "In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443," <i>Transplantation Proceedings</i> , 23(2): 10-14 (1991)
	CC	Anderson and Sartorelli, "Inosinic Acid Dehydrogenase of Sarcoma 180 Cells", <i>J. Biol. Chem.</i> , 243(18):4762-4768 (1968)
y	CD	Annenkov and Chernajovsky, "Engineering mouse T lymphocytes specific to type II collagen by transduction with a chimeric receptor consisting of a single chain Fv and TCR zeta," <i>Gene Therapy</i> , 7: 714-722 (2000)

EXAMINER

DATE CONSIDERED

2.20.03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24751-2502SERIAL NO.  
09/846,637LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Jensen, Michael C.FILING DATE  
April 30, 2001GROUP  
1632

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

yo	CE	Antonino and Wu, "Human IMP Dehydrogenase Catalyzes the Dehalogenation of 2-Fluoro- and 2-Chloroinosine 5'-Monophosphate in the Absence of NAD", <i>Biochem.</i> , <u>33</u> :1753-1759 (1994)
	CF	Arend <i>et al.</i> , "Inhibition of the Production and Effects of Interleukin-1 and Tumor Necrosis Factor $\alpha$ in Rheumatoid Arthritis", <i>Arthritis Rheum.</i> , <u>38</u> :151-160 (1995)
	CG	Arend, "Interleukin-1 Receptor Antagonist", <i>Adv. Immunol.</i> , <u>54</u> :167-227 (1993)
	CH	Bader <i>et al.</i> , "Expression, purification, and characterization of histidine-tagged rat and human flavoenzyme dihydroorotate dehydrogenase," <i>Protein Expression and Purification</i> , <u>13</u> : 414-422 (1998)
	CI	Ballas <i>et al.</i> , "Program No. 201: Transplantation, Detection and Selection of Donor BOne Marrow Stromal Cells in <i>In Vivo</i> ," <i>The Third Annual Meeting of the American Society of Gene Therapy (ASGT) Denver, Colorado, May 31- June 4, 2000</i> <a href="http://www/apnet.com/www/journal/asgt/8285.html">http://www/apnet.com/www/journal/asgt/8285.html</a> (04/26/01)
	CJ	Baltimore, "Gene therapy. Intracellular Immunization", <i>Nature</i> , <u>335</u> :395-396 (1988)
	CK	Balzarini <i>et al.</i> , "Eicar (5-Ethynyl-1- $\beta$ -D-ribofuranosylimidazole-4-carboxamide) A Novel Potent Inhibitor of inosinate dehydrogenase activity and Guanylate Biosynthesis", <i>J. Biol. Chem.</i> , <u>268</u> (33):24591-24598 (1993)
	CL	Barnes <i>et al.</i> , "Selective inhibition of human molt-4 leukemia type II inosine 5'-monophosphate dehydrogenase by the 1,5-diazabicyclo[3.1.0]hexane-2,4-diones," <i>Biochemistry</i> , <u>39</u> : 13641-13650 (2000)
	CM	Beauséjour <i>et al.</i> , "Program No. 217: <i>In Vitro</i> Selection of Cytidine Deaminase-transduced Cells," <i>The Third Annual Meeting of the American Society of Gene Therapy (ASGT) Denver, Colorado, May 31- June 4, 2000</i> <a href="http://www/apnet.com/www/journal/asgt/8355.html">http://www/apnet.com/www/journal/asgt/8355.html</a> (04/26/01)
	CN	Berardi <i>et al.</i> , "Functional Isolation and Characterization of Human Hematopoietic Stem Cells", <i>Science</i> , <u>267</u> :104 (1995)
	CO	Benoist and Chambon, " <i>In vivo</i> sequence requirements of the SV40 early promoter region", <i>Nature</i> , <u>290</u> :304-310 (1981)
yo	CP	Bevec <i>et al.</i> , "Constitutive Expression of Chimeric <i>Neo</i> -Rev Response Element Transcripts Suppresses HIV-1 Replication in Human CD4 T Lymphocytes", <i>Hum. Gene. Ther.</i> , <u>5</u> :193-201 (1994)

EXAMINER

DATE CONSIDERED

2.2003

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24751-2502	SERIAL NO. 09/846,637
	APPLICANT Jensen, Michael C.	
	FILING DATE April 30, 2001	GROUP 1632
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

y	CQ	Birkeland <i>et al.</i> , "Preventing acute rejection, epstein-barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol," <i>Transplantation</i> , <u>67(9)</u> : 1209-1214 (1999)
	CR	Boritzki <i>et al.</i> , "Guanosine-5'-phosphate synthetase and guanosine-5'-phosphate kinase in rat hepatomas and kidney tumors," <i>Biochimica et Biophysica Acta</i> , <u>658</u> : 102-110 (1981)
	CS	Bout, "Prospects for human gene therapy," <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <u>31(2)</u> : 175-179 (1996)
	CT	Braun <i>et al.</i> , "Preclinical studies of lymphocyte gene therapy for mild hunter syndrome (mucopolysaccharidosis type II)," <i>Human Gene Therapy</i> , <u>7</u> : 283-290 (1996)
	CU	Briggs <i>et al.</i> , "Successful mycophenolate mofetil treatment of glomerular disease," <i>American J Kidney Diseases</i> , <u>31(2)</u> : 213-217 (1998)
	CV	Brinster <i>et al.</i> , "Regulation of metallothionein—thymidine kinase fusion plasmids injected into mouse eggs", <i>Nature</i> , <u>296</u> :39-42 (1982)
	CW	Buckley, R., "Gene therapy for human SCID: dreams become reality," <i>Nature Medicine</i> , <u>6(6)</u> : 623-624 (2000)
	CX	Bunnell <i>et al.</i> , "High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes", <i>Proc. Natl. Acad. Sci. USA</i> , <u>90</u> :7739 (1995)
	CY	Cahill <i>et al.</i> , "ANF-C-receptor-mediated inhibition of aortic smooth muscle cell proliferation and thymidine kinase activity", <i>Amer. J. Phys.</i> , <u>266</u> :R194-R203 (1994)
	CZ	Cann <i>et al.</i> , "High efficiency transfection of primary human lymphocytes and studies of gene expression", <i>Oncogene</i> , <u>3</u> :123 (1988)
	DA	Carr <i>et al.</i> , "Characterization of Human Type I and Type II IMP Dehydrogenases", <i>J. Biol. Chem.</i> , <u>268(36)</u> :27286-27290 (1993)
	DB	Carswell and Alwine, "Efficiency of Utilization of the Simian Virus 40 Late Polyadenylation Site: Effects of Upstream Sequences", <i>Mol. Cell. Biol.</i> , <u>9(10)</u> :4248-4258 (1989)
	DC	Cavazzana-Calvo <i>et al.</i> , "Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease," <i>Science</i> , <u>288</u> : 669-672 (2000)
y	DD	Chapman <i>et al.</i> , "Effect of intron A from human cytomegalovirus (Tony) immediate-early gene on heterologous expression in mammalian cells", <i>Nun. Acids Res.</i> , <u>19(14)</u> :3979-3986 (1991)

EXAMINER



DATE CONSIDERED

2.20.03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24751-2502SERIAL NO.  
09/846,637LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Jensen, Michael C.FILING DATE  
April 30, 2001GROUP  
1632

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

48	DE	Chapuis <i>et al.</i> , "Effects of mycophenolic acid on human immunodeficiency virus infection <i>in vitro</i> and <i>in vivo</i> ", <i>Nature Medicine</i> , <u>6</u> (7):762-768 (2000)
	DF	Chen <i>et al.</i> , "Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium," <i>Cancer Research</i> , <u>52</u> : 3521-3527 (1992)
	DG	Christopherson and Lyons, "Potent inhibitors of De Novo Pyrimidine and Purine Biosynthesis as Chemotherapeutic Agents", <i>Med. Res. Rev.</i> , <u>10</u> (4):505-548 (1990)
	DH	Claudio <i>et al.</i> , " <del>Adenoviral RB2/p130 Gene Transfer Inhibits Smooth Muscle Cell Proliferation and Prevents Restenosis After Angioplasty</del> ", <i>Circ. Res.</i> , <u>85</u> :1032-1039
	DI	Cleaveland <i>et al.</i> , "Identification of a Novel Inhibitor (NSC 665564) of Dihydroorotate Dehydrogenase with a Potency Equivalent to Brequinar", <i>Biochem. Biophys. Res. Commun.</i> , <u>223</u> :654-650 (1996)
	DJ	Cleaveland <i>et al.</i> , "Site of Action of Two Novel Pyrimidine Biosynthesis Inhibitors Accurately Predicted by the Compare Program", <i>Biochem. Pharmacol.</i> , <u>49</u> (7):947-954 (1995)
	DK	Cobbs <i>et al.</i> , "Retroviral expression of recombinant p47 <sup>phox</sup> protein by epstein-barr virus-transformed B lymphocytes from a patient with autosomal chronic granulomatous disease," <i>Blood</i> , <u>79</u> (7): 1829-1835 (1992)
	DL	Cochlovius <i>et al.</i> , "Stable expression of a retrovirally transferred adhesion molecule in a human melanoma-specific cytotoxic T lymphocyte clone", <i>Cancer Immunol. Immunother.</i> , <u>46</u> :61-66 (1998)
	DM	Colby <i>et al.</i> , "Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design," <i>Proc Natl Acad Sci, USA</i> , <u>96</u> : 3531-3536 (1999)
	DN	Cole <i>et al.</i> , "Characterization of the Functional Specificity of a Cloned T-Cell Receptor Heterodimer Recognizing the MART-1 Melanoma Antigen", <i>Cancer Res.</i> , <u>55</u> :748-752 (1995)
	DO	Collart <i>et al.</i> , "Increased Inosine-5'-phosphate Dehydrogenase Gene Expression in Solid Tumor Tissues and Tumor Cell Lines", <i>Cancer Res.</i> , <u>52</u> :5826-5828 (1992)
	DP	Cooney <i>et al.</i> , "The Conversion of 2- $\beta$ -D-Ribofuranosylthiazole-4-Carboxamide to an Analogue of NAD with Potent IMP Dehydrogenase-Inhibitory Properties", <i>Biochem. Pharmacol.</i> , <u>31</u> (11):2133-2136 (1982)
49	DQ	Copeland <i>et al.</i> , "Recombinant Human Dihydroorotate Dehydrogenase: Expression, Purification, and Characterization of a Catalytically Functional Truncated Enzyme", <i>Arch Biochem. Biophys.</i> , <u>323</u> (1):79-86 (1995)

EXAMINER

DATE CONSIDERED

2-20-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**


FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24751-2502SERIAL NO.  
09/846,637LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Jensen, Michael C.FILING DATE  
April 30, 2001GROUP  
1632

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

48	DR	Coppa <i>et al.</i> , "Bone marrow transplantation in a hunter patient with P266H mutation," <i>International Journal of Molecular Medicine</i> , <u>4</u> : 433-436 (1999)
	DS	Corna <i>et al.</i> , "Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease," <i>Kidney International</i> , <u>51</u> : 1583-1589 (1997)
	DT	Cron <i>et al.</i> , "Consistent transient transfection of DNA into non-transformed human and murine T-lymphocytes", <i>J. Immunol. Meth.</i> , <u>205</u> :145-150 (1997)
	DU	Crystal, "Transfer of genes to humans: early lessons and obstacles to success," <i>Science</i> , <u>270</u> : 404-410 (1995)
	DV	Czech <i>et al.</i> , "The antiproliferative effect of malononitrilamides (MNAs) on vascular smooth muscle cells is antagonized by exogenous uridine", <i>Inflamm. Res.</i> , <u>48(suppl.2)</u> :S128-S129 (1999)
	DW	Czech <i>et al.</i> , "Inhibition of smooth Muscle Cell Proliferation by A77-1726 and Its Derivatives can be Antagonized by Uridine", <i>Int. J. Immunother.</i> , <u>XIV(4)</u> :185-191 (1999)
	DX	Database EMBL online, Nucleotide Accession No. AX061346, "Sequence 1 from patent WO0100847," January 22, 2001
	DY	Database EMBL online, Nucleotide Accession No. M94065, "Human dihydroorotate dehydrogenase mRNA, 3' end," October 7, 1994
	DZ	Dayton <i>et al.</i> , "Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression," <i>Journal of Immunology</i> , <u>152</u> : 984-991 (1994)
	EA	De Boer <i>et al.</i> , "The <i>tac</i> promoter: A functional hybrid derived from the <i>trp</i> and <i>lac</i> promoters", <i>Proc. Natl. Acad. Sci. USA</i> , <u>80</u> :21-25 (1983)
	EB	Dhar <i>et al.</i> , "Transfer of Chinese Hamster Chromosome 1 to Mouse Cells and Regional Assignment of 7 Genes: A Combination of Gene Transfer and Microcell Fusion", <i>Somatic Cell Mol. Genet.</i> , <u>10(6)</u> :547-559 (1984)
	EC	Duan <i>et al.</i> , "Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody", <i>Proc. Natl. Acad. Sci. USA</i> , <u>91</u> :5015-5019 (1994)
	ED	Dube and Cournoyer, "Gene therapy: here to say," <i>Can Med Assoc J</i> , <u>152(10)</u> : 1605-1613 (1995)
49	EE	Elliot and Weber, "Proliferation-linked Increase in Phosphoribosylformylglycinamidine synthetase activity (EC 6.3.5.3) <sup>1</sup> ," <i>Cancer Research</i> , <u>44</u> : 2430-2434 (1984)

EXAMINER



DATE CONSIDERED

2-20-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**



FORM PTO-1449 (Modified)  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 24751-2502	SERIAL NO. 09/846,637
	APPLICANT Jensen, Michael C.	
	FILING DATE April 30, 2001	GROUP 1632

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

y	EF	Enriquez-Harris <i>et al.</i> , "A pause site for RNA polymerase II is associated with termination of transcription", <i>EMBO J.</i> , <u>10</u> (7):1833-1842 (1991)
	EG	Eshhar <i>et al.</i> , "Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the $\gamma$ or $\zeta$ subunits of the immunoglobulin and T-cell receptors", <i>Proc. Natl. Acad. Sci. USA</i> , <u>90</u> :720-724 (1993)
	EH	Eugui <i>et al.</i> , "Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice," <del><i>Scand. J. Immunol.</i>, <u>33</u>: 175-183 (1991)</del>
	EI	Eugui <i>et al.</i> , "Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion," <i>Scand. J. Immunol.</i> , <u>33</u> : 161-173 (1991)
	EJ	Evans <i>et al.</i> , "Gene therapy for autoimmune disorders," <i>Journal of Clinical Immunology</i> , <u>20</u> (5): 334-346 (2000)
	EK	Fairbanks <i>et al.</i> , "Importance of Ribonucleotide Availability to Proliferating T-lymphocytes from Healthy Humans", <i>J. Biol. Chem.</i> , <u>270</u> (50):29682-29689 (1995)
	EL	Fathman <i>et al.</i> , "Gene Therapy for Autoimmune Disease," <i>Clinical Immunology</i> , <u>95</u> (1): S39-S43 (2000)
	EM	Favre <i>et al.</i> , "Critical aspects of viral vectors for gene transfer into the kidney," <i>J Am Soc Nephrol</i> , <u>11</u> : S149-S153 (2000)
	EN	Fiehn <i>et al.</i> , "Bone marrow-derived cells as carriers of recombinant immunomodulatory cytokine genes to lymphoid organs," <i>Cancer Gene Therapy</i> , <u>7</u> (8): 1105-1112 (2000)
	EO	Finck <i>et al.</i> , "Treatment of Murine Lupus with CTLA4Ig", <i>Science</i> , <u>265</u> :1225-1227 (1994)
	EP	Finer <i>et al.</i> , "kat: A High-Efficiency Retroviral Transduction System for Primary Human T Lymphocytes", <i>Blood</i> , <u>83</u> (1):43 (1994)
	EQ	Franklin <i>et al.</i> , "A Novel Series of Non-nucleoside Inhibitors of Inosine 5'-Monophosphate Dehydrogenase with Immunosuppressive Activity", <i>Biochem. Pharmacol.</i> , <u>58</u> :867-876 (1999)
	ER	Freese <i>et al.</i> , "Partial Purine Deprivation Causes Sporulation of <i>Bacillus subtilis</i> in the Presence of Excess Ammonia, Glucose and Phosphate", <i>J. Gen. Microbiol.</i> , <u>115</u> :193-205 (1979)
y	ES	Fry and Wood, "Gene therapy: potential applications in clinical transplantation," <i>Expert Reviews in Molec. Med.</i> , 1-24 (1999)

EXAMINER

DATE CONSIDERED

2.20.03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24751-2502	SERIAL NO. 09/846,637
	APPLICANT Jensen, Michael C.	
	FILING DATE April 30, 2001	GROUP 1632

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

YJP	ET	Fujita <i>et al.</i> , "Enhancement of T Cell Receptor Signaling of Tumor-infiltrating Lymphocytes by Retrovirally Mediated fyn Gene Transduction", <i>Jpn. J. Cancer Res.</i> , <u>85</u> :1073-1079 (1994)
	EU	Geogantas <i>et al.</i> , "Antigen-specific induction of peripheral T cell tolerance <i>in vivo</i> by codelivery of DNA vectors encoding antigen and fas ligand," <i>Human Gene Therapy</i> , <u>11</u> : 851-858 (2000)
	EV	Gharebaghi <i>et al.</i> , "p210 Bcr-Abl confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene," <i>Leukemia</i> , <u>8</u> (8): 1257-1263 (1994)
	EW	Glenney <i>et al.</i> , "Mapping the Fodrin Molecule with Monoclonal Antibodies", <i>J. Mol. Biol.</i> , <u>167</u> :275-293 (1983)
	EX	Goldman <i>et al.</i> , "Bone Marrow Transplantation for Chronic Myelogenous Leukemia in Chronic Phase", <i>Ann. Intern. Med.</i> , <u>108</u> :806-814 (1988)
	EY	Goodwin and Rottman, "The 3'-Flanking Sequence of the Bovine Growth Hormone Gene contains Novel Elements Required for Efficient and Accurate Polyadenylation", <i>J. Biol. Chem.</i> , <u>267</u> (23):16330-16334 (1992)
	EZ	Greaves <i>et al.</i> , "Activation of human T and B lymphocytes by polyclonal mitogens", <i>Nature</i> , <u>248</u> :698-701 (1974)
	FA	Greene <i>et al.</i> , "Inhibition of Dihydroorotate Dehydrogenase by the Immunosuppressive Agent Leflunomide", <i>Biochem. Pharmacol.</i> , <u>50</u> (6):861-867 (1995)
	FB	Greer and Wellman, "Isolation and characterization of guanine auxotrophs in <i>Neurospora crassa</i> ", <i>Can. J. Microbiol.</i> , <u>26</u> :1412-1415 (1980)
	FC	Grosschedl <i>et al.</i> , "Introduction of a $\mu$ Immunoglobulin Gene into the Mouse Germ Line: Specific Expression in Lymphoid Cells and Synthesis of Functional Antibody", <i>Cell</i> , <u>38</u> :647-658 (1984)
	FD	Grundmann-Kollmann <i>et al.</i> , "Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases," <i>J Am Acad Dermatol</i> , <u>40</u> : 957-960 (1999)
	FE	Gu <i>et al.</i> , "Assignment of the Human Type I IMP Dehydrogenase Gene (IMPDH1) to Chromosome 7q31.3-q32", <i>Genomics</i> , <u>24</u> :179-181 (1994)
	FF	Haas <i>et al.</i> , "Regulatory mechanism in glomerular mesangial cell proliferation", <i>J. Nephrol.</i> , <u>12</u> :405-415 (1999)
YJP	FG	Halloran, "Molecular mechanisms of new immunosuppressants", <i>Clin. Transplantation</i> , <u>10</u> :118-123 (1996)

EXAMINER

DATE CONSIDERED 2.20.03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24751-2502SERIAL NO.  
09/846,637LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Jensen, Michael C.FILING DATE  
April 30, 2001GROUP  
1632

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

40	FH	Hammer <i>et al.</i> , "Diversity of Alpha-Fetoprotein Gene Expression in Mice Is Generated by a Combination of Separate Enhancer Elements", <i>Science</i> , <u>235</u> :53-58 (1987)
	FI	Hanahan <i>et al.</i> "Heritable formation of pancreatic $\beta$ -cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes", <i>Nature</i> , <u>315</u> :115-122 (1985)
	FJ	Hara <i>et al.</i> , "Overexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells," <i>Biochem Biophys Res Commun.</i> , <u>216</u> (3): 862-867 (1995)
	FK	Hauser <i>et al.</i> , "Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion", <i>Nephrol. Dial. Transplant.</i> , <u>14</u> :58-63 (1999)
	FL	Hayashi <i>et al.</i> , "In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model", <i>Gene Therapy</i> , <u>7</u> :1664-1671 (2000)
	FM	Heinschink <i>et al.</i> , "In vitro effects of mycophenolic acid on cell cycle and activation of human lymphocytes," <i>Clinica Chimica Acta</i> , <u>300</u> : 23-28 (2000)
	FN	Henderson <i>et al.</i> , "Human Dendritic Cells Genetically Engineered to Express High Levels of the Human Epithelial Tumor Antigen Mucin (MUC-1)", <i>Cancer Res.</i> , <u>56</u> :3763-3770 (1996)
	FO	Henderson, P., "A Linear Equation that Describes the Steady-State Kinetics of Enzymes and Subcellular Particles Interacting with Tightly Bound Inhibitors", <i>Biochem. J.</i> , <u>127</u> :321 (1972)
	FP	Heslop <i>et al.</i> , "Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes", <i>Nat. Med.</i> , <u>2</u> :551-555 (1996)
	FQ	Hirsch <i>et al.</i> , "Antifection: A New Method for Targeted Gene Transfection", <i>Transpl. Proc.</i> , <u>25</u> :138-139 (1993)
	FR	Holmen <i>et al.</i> , "Efficient Lipid-Mediated Transfection of DNA into Primary Rat Hepatocytes", <i>In Vitro Cell Dev. Biol. Anim.</i> , <u>31</u> :347-351 (1995)
	FS	Holmes <i>et al.</i> , "Human IMP Dehydrogenase Kinetics and Regulatory Properties", <i>Biochem. Biophys. Acta</i> , <u>364</u> :209-217 (1974)
	FT	Hood and Zarembski, "Mycophenolate mofetil: A unique immunosuppressive agent", <i>Am. J. Health-Syst. Pharm.</i> , <u>54</u> :285-294 (1997)
40	FU	Hsu <i>et al.</i> , "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells", <i>Natl. Med.</i> , <u>2</u> :52-58 (1995)

EXAMINER

Yan

DATE CONSIDERED 2.20.03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24751-2502	SERIAL NO. 09/846,637
	APPLICANT Jensen, Michael C.	
	FILING DATE April 30, 2001	GROUP 1632

## LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

FY	FV	Huberman <i>et al.</i> , "Regulation and Role of Inosine-5'-Monophosphate Dehydrogenase in Cell Replication, Malignant Transformation, and Differentiation", <i>Adv. Exp. Med. Biol.</i> , <u>370</u> :741-746 (1994)
FX	FW	Hughes <i>et al.</i> , "Transcriptional Regulation of the Interleukin-2 Gene in Normal Human Peripheral Blood T Cells", <i>J. Biol. Chem.</i> , <u>271</u> (10):5369-5377 (1996)
FY	FX	Hwu <i>et al.</i> , "Functional and Molecular Characterization of Tumor-Infiltrating Lymphocytes Transduced with Tumor Necrosis Factor- $\alpha$ cDNA for the Gene Therapy of Cancer in Humans", <i>J. Immunol.</i> , <u>150</u> :4104-4115 (1993)
FZ	FY	Hwu <i>et al.</i> , "In Vivo Antitumor Activity of T Cells Redirected with Chimeric Antibody/T-Cell Receptor Genes", <i>Cancer Res.</i> , <u>55</u> :3369-3373 (1995)
GA	FZ	Hwu <i>et al.</i> , "Lysis of Ovarian Cancer Cells by Human Lymphocytes Redirected with a Chimeric Gene Composed of an Antibody Variable Region and the Fc Receptor $\gamma$ Chain", <i>J. Exp. Med.</i> , <u>178</u> :361-366 (1993)
GB	GA	Ichimura and Levy, "Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus," <i>Virology</i> , <u>211</u> : 554-560 (1995)
GC	GB	Jaalouk <i>et al.</i> , "Glucocorticoid-Inducible Retrovector for Regulated Transgene Expression in Genetically Engineered Bone Marrow Stromal Cells", <i>Human Gene Therapy</i> , <u>11</u> :1837-1849 (2000)
GD	GC	Jackson <i>et al.</i> , "IMP dehydrogenase, an enzyme linked with proliferation and malignancy", <i>Nature</i> , <u>256</u> :331-333 (1975)
GE	GD	Jensen <i>et al.</i> , "Human T lymphocyte genetic modification with naked DNA," <i>Molecular Therapy</i> , <u>1</u> (1): 49-55 (2000)
GF	GE	Jerne <i>et al.</i> , "The Agar Plaque Technique for Recognizing Antibody-producing Cells", <i>Cell Bound Antibodies</i> , Amos and Kaprowski, eds. (Wistar Institute Press, Philadelphia, 1963) p. 109-125
GG	GF	Kamboj <i>et al.</i> , "Mapping of a Cell-binding Domain in the Cell Adhesion Molecule gp80 of <i>Dictyostelium discoideum</i> ", <i>J. Cell Biol.</i> , <u>107</u> :1835-1843 (1988)
GH	GG	Kashles <i>et al.</i> , "Ligand-induced stimulation of epidermal growth factor receptor mutants with altered transmembrane regions", <i>Proc. Natl. Acad. Sci. USA</i> , <u>85</u> :9576-9571 (1988)
GI	GH	Keller <i>et al.</i> , "Transgene expression, but not gene delivery, is improved by adhesion-assisted lipofection of hematopoietic cells," <i>Gene Therapy</i> , <u>6</u> : 931-938 (1999)
GI	GI	Kelley and Sukhatme, "Gene transfer in the kidney," <i>American Journal of Physiology - Renal Physiology</i> , <u>276</u> (1): F1-F9 (1999)

EXAMINER

DATE CONSIDERED 2.20.03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24751-2502	SERIAL NO. 09/846,637
	APPLICANT Jensen, Michael C.	
	FILING DATE April 30, 2001	GROUP 1632

## LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

yjd	GJ	Kelsey <i>et al.</i> , "Species- and tissue-specific expression of human $\alpha_1$ -antitrypsin in transgenic mice", <i>Genes and Devel.</i> , <u>1</u> :161-171 (1987)
	GK	Kiguchi <i>et al.</i> , "Induction of Cell Differentiation in Melanoma Cells by Inhibitors of IMP Dehydrogenase: Altered Patterns of IMP Dehydrogenase Expression and Activity", <i>Cell Growth Differ.</i> , <u>1</u> :259-270 (1990)
	GL	Kim <i>et al.</i> , "Use of the human elongation factor 1 $\alpha$ promoter as a versatile and efficient expression system", <i>Gene</i> , <u>91</u> :217-223 (1990)
	GM	Kitamura and Kawachi, "Creation of an in vivo cytosensor using engineered mesangial cells," <i>J Clin. Invest.</i> , <u>100</u> (6): 1394-1399 (1997)
	GN	Kitamura <i>et al.</i> , "Gene Delivery into the Renal Glomerulus by Transfer of Genetically Engineered, Autologous Mesangial Cells", <i>Exp. Nephrol.</i> , <u>4</u> :56-69 (1994)
	GO	Kitamura <i>et al.</i> , "Gene Transfer into the Rat Renal Glomerulus via a Mesangial Cell Vector: Site-specific Delivery, In Situ Amplification, and Sustained Expression of an Exogenous Gene In Vivo", <i>J. Clin. Invest.</i> , <u>94</u> :497-505 (1994)
	GP	Kitamura, "Gene Delivery into the Glomerulus via Mesangial Cell Vectors", <i>Exp. Nephrol.</i> , <u>5</u> :118-125 (1997)
	GQ	Kitamura, M., "Renal transfer of genetically engineered cells," <i>J Am Soc Nephrol</i> , <u>11</u> : S154-S158 (2000)
	GR	Kluth <i>et al.</i> , "Gene transfer into inflamed glomeruli using macrophages transfected with adenovirus," <i>Gene Therapy</i> , <u>7</u> : 263-270 (2000)
	GS	Knecht and Löffler, "Redoxal as a new leadstructure for dihydroorotate dehydrogenase inhibitors: a kinetic study of the inhibition mechanism", <i>FEBS Lett.</i> , <u>467</u> :27-30 (1999)
	GT	Knecht and Löffler, "Species-related Inhibition of Human and Rat Dihydroorotate Dehydrogenase by Immunosuppressive Isoxazol and Cinchoninic Acid Derivatives", <i>Biochem. Pharmacol.</i> , <u>56</u> :1259-1264 (1998)
	GU	Knecht <i>et al.</i> , "Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovirus expression vector system, and kinetic investigation of the purified recombinant enzyme," <i>Eur J Biochem</i> , <u>240</u> : 292-301 (1996)
	GV	Knecht <i>et al.</i> , "Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid", <i>Chemico-Biological Interactions</i> , <u>124</u> :61-76 (2000)
yjd	GW	Knecht <i>et al.</i> , "Rat Dihydroorotate Dehydrogenase: isolation of the recombinant enzyme from mitochondria of insect cells," <i>Protein Expression and Purification</i> , <u>10</u> : 89-99 (1997)

EXAMINER

Ymk

DATE CONSIDERED

2-20-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24751-2502	SERIAL NO. 09/846,637
	APPLICANT Jensen, Michael C.	
	FILING DATE April 30, 2001	GROUP 1632

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

GX	Kobayashi <i>et al.</i> , "Anti-arthritis effects of KF20444, a new immunosuppressive compound inhibiting dihydroorotate dehydrogenase, on rat collagen-induced arthritis," <i>Inflammation Research</i> , <u>50</u> : 24-31 (2001)
GY	Kollias <i>et al.</i> , "Regulated Expression of Human $\gamma$ -, $\beta$ -, and Hybrid $\gamma\beta$ -Globin Genes in Transgenic Mice: Manipulation of the Developmental Expression Patterns", <i>Cell</i> , <u>46</u> :89-94 (1986)
GZ	Konno <i>et al.</i> , "Expression of Human IMP Dehydrogenase Types I and II in <i>Escherichia coli</i> and Distribution in Human Normal Lymphocytes and Leukemic Cell Lines", <i>J. Biol. Chem.</i> , <u>266</u> (1):506-509 (1991)
HA	Krumlauf <i>et al.</i> , "Developmental Regulation of $\alpha$ -Fetoprotein Genes in Transgenic Mice", <i>Mol. Cell. Biol.</i> , <u>5</u> :1639-1648 (1985)
HB	Kuchle <i>et al.</i> , "Prevention of Kidney and Skin Graft Rejection in Rats by Leflunomide, a New Immunomodulating Agent", <i>Transplant. Proc.</i> , <u>23</u> (1):1803-1806 (1990)
HC	Kusumi <i>et al.</i> , "Dual Inhibitory Effect of Bredinin", <i>Cell. Biochem. Function</i> , <u>7</u> :201-204 (1988)
HD	Lambert, "Functional complementation of ataxia____telangiectasia group D (AT-D) cells by microcell-mediated chromosome transfer and mapping of the AT-D locus to the region 11q22____23", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , <u>88</u> :5907-5911 (1991)
HE	Lamphere <i>et al.</i> , "Novel chimeric p16 and p27 molecules with increased antiproliferative activity for vascular disease gene therapy", <i>J. Mol. Med.</i> , <u>78</u> (8):451-459 (2000)
HF	Leavitt <i>et al.</i> , "Transfer of an Anti-HIV-1 Ribozyme Gene into Primary Human Lymphocytes", <i>Hum. Gene. Ther.</i> , <u>5</u> :1115-1120 (1994)
HG	Le Bolc'h <i>et al.</i> , "Cationic Phosphonolipids as non Viral Vectors for DNA Transfection", <i>Tetrahedron Lett.</i> , <u>36</u> (37):6681-6684 (1995)
HH	Leder <i>et al.</i> , "Consequences of Widespread Deregulation of the <i>c-myc</i> Gene in Transgenic Mice: Multiple Neoplasms and Normal Development", <i>Cell</i> , <u>45</u> :485-495 (1986)
HI	Lee <i>et al.</i> , "Bioavailability Improvement of Mycophenolic Acid Through Amino Ester Derivatization", <i>Pharm. Res.</i> , <u>7</u> (2):161-166 (1990)
HJ	Lee <i>et al.</i> , "Inhibition of Human Immunodeficiency Virus Type 1 in Human T Cells by a Potent Rev Response Element Decoy Consisting of the 13-Nucleotide Minimal Rev-Binding Domain", <i>J. Virol.</i> , <u>68</u> (12):8254-8264 (1994)
HK	Levitt <i>et al.</i> , "Definition of an efficient synthetic poly(A) site", <i>Genes Dev.</i> , <u>3</u> :1019-1025 (1989)

EXAMINER

York

DATE CONSIDERED

2-20-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24751-2502	SERIAL NO. 09/846,637
	APPLICANT Jensen, Michael C.	
	FILING DATE April 30, 2001	GROUP 1632

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

yfn	HL	Liszewicz <i>et al.</i> , "Antitumor gene therapy: a candidate for late-stage AIDS patients", <i>Gene Ther.</i> , <u>2</u> :218-222 (1995)
	HM	Löeffler <i>et al.</i> , "Gene Transfer into Primary and Established Mammalian Cell Lines with Lipopolyamine-Coated DNA", <i>Meth. Enzymol.</i> , <u>217</u> :599-618 (1993)
	HN	Löffler <i>et al.</i> , "Catalytic enzyme histochemistry and biochemical analysis of dihydroorotate dehydrogenase/oxidase and succinate dehydrogenase in mammalian tissues, cells and mitochondria", <i>Histochem. Cell Biol.</i> , <u>105</u> (2):119-128 (1996)
	HO	Löffler <i>et al.</i> , "Dihydroorotate dehydrogenase," <i>Purine and Pyrimidine Metabolism in Man</i> /X, Chapter 99: 507-513, Griesmacher <i>et al.</i> ed, Plenum Press, New York (1998)
	HP	Löffler <i>et al.</i> , "The "Anti-Pyrimidine Effect" of Hypoxia and Brequinar Sodium (NSC 368390) is of Consequence for Tumor Cell Growth", <i>Biochem. Pharmacol.</i> , <u>43</u> (10):2281-2287 (1992)
	HQ	Lorenzo <i>et al.</i> , "A rapid method of epitope mapping", <i>Eur. J. Biochem.</i> , <u>176</u> :53-60 (1988)
	HR	Lui <i>et al.</i> , "Modulation of IMP Dehydrogenase Activity and Guanylate Metabolism by Tiazofurin (2- $\beta$ -D-ribofuranosylthiazole-4-carboxamide)", <i>J. Biol. Chem.</i> , <u>259</u> (8):5078-5082 (1984)
	HS	Lyons <i>et al.</i> , "Effects of Brequinar and Ciprofloxacin on <i>De Novo</i> Nucleotide Biosynthesis in Mouse L1210 Leukemia", <i>Biochem. International</i> , <u>22</u> (6):939-950 (1990)
	HT	MacDonald, "Expression of the Pancreatic Elastase I Gene in Transgenic Mice", <i>Hepatol.</i> , <u>7</u> :425-515 (1987)
	HU	Maciejewski <i>et al.</i> , "Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection <i>in vitro</i> ", <i>Nat. Med.</i> , <u>1</u> (7):667-673 (1995)
	HV	Magasanik <i>et al.</i> , "Enzymes Essential for the Biosynthesis of Nucleic Acid Guanine; Inosine 5'-Phosphate Dehydrogenase of <i>Aerobacter Aerogenes</i> ", <i>J. Biol. Chem.</i> , <u>226</u> :339-350 (1957)
	HW	Magram <i>et al.</i> , "Developmental regulation of a cloned adult $\beta$ -globin gene in transgenic mice", <i>Nature</i> , <u>315</u> :338-340 (1985)
	HX	Maillard <i>et al.</i> , "Percutaneous delivery of the <i>gax</i> gene inhibits vessel stenosis in a rabbit model of balloon angioplasty", <i>Cardiovascular Res.</i> , <u>35</u> :536-546 (1997)
yfn	HY	Mann <i>et al.</i> , "Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomized, controlled trial", <i>Lancet</i> , <u>354</u> (9189):1493-1498 (1999)

EXAMINER

yfn

DATE CONSIDERED

2-20-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**


FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24751-2502	SERIAL NO. 09/846,637
	APPLICANT Jensen, Michael C.	
	FILING DATE April 30, 2001	GROUP 1632

## LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

40	HZ	Mann, "Gene therapy for peripheral arterial disease," <i>Molecular Medicine Today</i> , <u>6</u> : 285-291 (2000)
	IA	Mannino and Gould-Fogerite, "Liposome Mediated Gene Transfer", <i>Biotechniques</i> , <u>6(7)</u> :682-690 (1988)
	IB	Margolis <i>et al.</i> , "Abacavir and Mycophenolic Acid, an Inhibitor of Inosine Monophosphate Dehydrogenase, Have Profound and Synergistic Anti-HIV Activity", <i>J. Acq. Immune Def. Synd.</i> , <u>21(5)</u> :362-370 (1999)
	IC	Marijnen <i>et al.</i> , "Studies on the incorporation of precursors into purine and pyrimidine nucleotides via 'de novo' and 'salvage' pathways in normal lymphocytes and lymphoblastic cell-line cells," <i>Biochimica et Biophysica Acta</i> , <u>1012</u> : 143-155 (1989)
	ID	Marmont <i>et al.</i> , "T-Cell Depletion of HLA-Identical Transplants in Leukemia", <i>Blood</i> , <u>78</u> :2120-2130 (1991)
	IE	Martin, <i>et al.</i> , "Human Marrow Transplantation: An Immunological Perspective", <i>Adv. Immunol.</i> , <u>40</u> :379 (1987)
	IF	Mason <i>et al.</i> , "The Hypogonadal Mouse: Reproductive Functions Restored by Gene Therapy", <i>Science</i> , <u>234</u> :1372-1378 (1986)
	IG	Masson <i>et al.</i> , "Allopurinol inhibits <i>de novo</i> purine synthesis in lymphoblasts of children with acute lymphoblastic leukemia," <i>Leukemia</i> , <u>10</u> : 56-60 (1996)
	IH	Martino <i>et al.</i> , "Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: a novel gene therapy approach," <i>Journal of Neuroimmunology</i> , <u>107</u> : 184-190 (2000)
	II	Martino <i>et al.</i> , "Cytokine gene therapy of autoimmune demyelination revisited using herpes simplex virus type-1-derived vectors," <i>Gene Therapy</i> , <u>7</u> : 1087-1093 (2000)
	IJ	Mathisen and Tuohy, "Gene therapy in experimental autoimmune encephalomyelitis," <i>Journal of Clinical Immunology</i> , <u>20(5)</u> : 327-333 (2000)
	IK	Mathisen <i>et al.</i> , "Th2 T cells expressing transgene PDGF-A serve as vectors for gene therapy in autoimmune demyelinating disease," <i>Journal of Autoimmunity</i> , <u>13</u> : 31-38 (1999)
	IL	May <i>et al.</i> , "Methotrexate dose-escalation studies in transgenic mice and marrow transplant recipients expressing drug-resistant dihydrofolate reductase activity," <i>The Journal Pharmacology and Experimental Therapeutics</i> , <u>278(3)</u> : 1444-1451 (1996)
40	IM	McKinnis <i>et al.</i> , "Bone Marrow transplantation in hunter syndrome," <i>Journal of Pediatrics</i> , <u>129(1)</u> : 145-148 (1996)

EXAMINER



DATE CONSIDERED

2.20.03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**



FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24751-2502	SERIAL NO. 09/846,637
	APPLICANT Jensen, Michael C.	
	FILING DATE April 30, 2001	GROUP 1632
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Up	IN	McNeill-Killary <i>et al.</i> , "Microcell Fusion", <i>Meth. Enzymol.</i> , <u>254</u> :133-152 (1995)
f	IO	Meinl <i>et al.</i> , "Encephalitogenic Potential of Myelin Basic Protein-Specific T Cells Isolated from Normal Rhesus Macaques", <i>Am. J. Pathol.</i> , <u>150</u> (2):445-453 (1997)
	IP	Miles <i>et al.</i> , "One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase," <i>Biochemistry</i> , <u>37</u> (24): 8615-8621 (1998)
	IQ	Millan <i>et al.</i> , "Assessment of mycophenolic acid-induced immunosuppression: a new approach," <i>Clinical Chemistry</i> , <u>46</u> (9): 1376-1383 (2000)
	IR	Moreira <i>et al.</i> , "Upstream sequence elements enhance poly(A) site efficiency of the C2 complement gene and are phylogenetically conserved", <i>EMBO J.</i> , <u>14</u> (15):3809-3819 (1995)
	IS	Moritz <i>et al.</i> , "A spacer region between the single chain antibody-and the CD3 $\zeta$ -chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity", <i>Gene Ther.</i> , <u>2</u> :539-546 (1995)
	IT	Morris, "Mechanisms of action of new immunosuppressive drugs," <i>Kidney International</i> , <u>49</u> (Supp.53): S26-S38 (1996)
	IU	Nagai <i>et al.</i> , "Proliferation-linked Regulation of Type II IMP Dehydrogenase Gene in Human Normal Lymphocytes and HL-60 Leukemic Cells", <i>Cancer Res.</i> , <u>52</u> :258-261 (1992)
	IV	Nagai <i>et al.</i> , "Selective up-regulation of type II inosine 5'-monophosphate dehydrogenase messenger RNA expression in human leukemias," <i>Cancer Research</i> , <u>51</u> : 3886-3890 (1991)
	IW	Nahman <i>et al.</i> , "Successful DNA transfer in cultured human mesangial cells using replication deficient recombinant adenovirus," <i>Journal of Investigative Medicine</i> , <u>46</u> (5): 204-209 (1998)
	IX	Nakamura <i>et al.</i> , "Adoptive Immunotherapy with Murine Tumor-specific T Lymphocytes Engineered to Secrete Interleukin 2", <i>Cancer Res.</i> , <u>54</u> :5757-5760 (1994)
	IY	Natsumeda <i>et al.</i> , "De Novo Guanylate Synthesis in the Commitment to Replication in Hepatoma 3924A Cells", <i>Cancer Res.</i> , <u>48</u> :507-511 (1988)
	IZ	Natsumeda <i>et al.</i> , "Two Distinct cDNAs for Human IMP Dehydrogenase", <i>J. Biol. Chem.</i> , <u>265</u> (9):5292-5295 (1990)
Up	JA	Neidhardt, <i>et al.</i> , "Expression and Characterization of <i>E. coli</i> -produced Soluble, Functional Human Dihydroorotate Dehydrogenase: a Potential Target of Immunosuppression", <i>J. Mol. Microbiol. Biotechnol.</i> , <u>1</u> (1):183-188 (1999)

EXAMINER

Up

DATE CONSIDERED

2.20.03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24751-2502	SERIAL NO. 09/846,637
	APPLICANT Jensen, Michael C.	
	FILING DATE April 30, 2001	GROUP 1632
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

40	JB	Nelson <i>et al.</i> , "Synthesis and Immunosuppressive Activity of Some Side-Chain Variants of Mycophenolic Acid", <i>J. Med. Chem.</i> , <u>33</u> :833-838 (1990)
	JC	Neyts <i>et al.</i> , "The antiherpesvirus activity of H2G [(R)-9-[4-Hydroxy-2-(Hydroxymethyl)Butyl]Guanine] Is Markedly Enhanced by the Novel Immunosuppressive Agent Mycophenolate Mofetil," <i>Antimicrobial Agents and Chemotherapy</i> , <u>42</u> (12): 3285-3289 (1998)
	JD	<del>Neyts <i>et al.</i>, "The Immunosuppressive Agent Mycophenolate Mofetil Markedly Potentiates the Activity of Lobucavir [1R-(1<math>\alpha</math>, 2<math>\beta</math>, 3<math>\alpha</math>)-9-[2,3-Bis(4-Hydroxymethyl)Cyclobutyl]Guanine Against Different Herpes Viruses", <i>Transplantation</i>, <u>67</u>(5):760-764 (1999)</del>
	JE	Neyts <i>et al.</i> , "The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of Acyclovir, Ganciclovir, and Penciclovir in vitro and in vivo," <i>Antimicrobial Agents and Chemotherapy</i> , <u>42</u> (2): 216-222 (1998)
	JF	Nijkamp and De Haan, "Genetic and Biochemical Studies of the Guanosine 5'-Monophosphate Pathway in <i>Escherichia Coli</i> ", <i>Biochim. Biophys. Acta</i> , <u>145</u> :31-40 (1967)
	JG	Noll <i>et al.</i> , "Program No. 685: Development of Preclinical Protocol for <i>In Vivo</i> Selection in Fanconi Anemia Gene Therapy," <i>The Third Annual Meeting of the American Society of Gene Therapy (ASGT) Denver, Colorado, May 31- June 4, 2000</i> <a href="http://www.apnet.com/www/journal/asgt/7623.html">http://www.apnet.com/www/journal/asgt/7623.html</a> (04/26/01)
	JH	Nousari <i>et al.</i> , "Mycophenolate mofetil in autoimmune and inflammatory skin disorders," <i>J Amer Acad Dermatol.</i> , <u>40</u> (2) part 1: 265-268 (1999)
	JI	Novak <i>et al.</i> , "In Vitro Transfection of Fresh Thymocytes and T Cells Shows Subset-Specific Expression of Viral Promoters", <i>Mol. Cell. Biol.</i> , <u>12</u> :1515-1527 (1992)
	JJ	Ornitz <i>et al.</i> , "Elastase I Promoter Directs Expression of Human Growth Hormone and SV40 T Antigen Genes to Pancreatic Acinar Cells in Transgenic Mice", <i>Cold Spring Harbor Symp. Quant. Biol.</i> , <u>50</u> :399-409 (1986)
	JK	Ouyang <i>et al.</i> , "Effects of adenoviral vector-mediated rat antisense AT <sub>1B</sub> gene transfer on neointima proliferation after rat carotid artery injury", <u>27</u> (5):381-383 (1999)
	JL	Pankiewicz, "Inhibitors of inosine monophosphate dehydrogenase as potential chemotherapeutic agents", <i>Exp. Opin. Ther. Patents</i> , <u>9</u> :55-65 (1999)
	JM	Perigaud <i>et al.</i> , "Nucleoside Analogues as Chemotherapeutic Agents: A Review", <i>Nucleosides and Nucleotides</i> , <u>11</u> (2-4):903-945 (1992)
40	JN	Philip <i>et al.</i> , "In Vivo Gene Delivery", <i>J. Biol. Chem.</i> , <u>268</u> :16087-16090 (1993)

EXAMINER



DATE CONSIDERED

2-20-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24751-2502	SERIAL NO. 09/846,637
	APPLICANT Jensen, Michael C.	
	FILING DATE April 30, 2001	GROUP 1632
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

42	JO	Pinkert <i>et al.</i> , "An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice", <i>Genes and Devel.</i> , <u>1</u> :268-276 (1987)
	JP	Poncet <i>et al.</i> , "Antifection: an antibody-mediated method to introduce genes into lymphoid cells in vitro and in vivo", <i>Gene Therapy</i> , <u>3</u> :731-738 (1996)
	JQ	Posmantur <i>et al.</i> , "A purine nucleoside phosphorylase (PNP) inhibitor induces apoptosis via caspase-3-like protease activity in MOLT-4 T cells," <i>Immunopharmacology</i> , <u>37</u> : 231-244 (1997)
	JR	Poston <i>et al.</i> , "Cardiothoracic Transplantation. Ex Vivo Gene Therapy Prevents Chronic Graft Vascular Disease in Cardiac Allografts", <i>J. Thorac. Cardiovasc. Surg.</i> , <u>116</u> :386-396 (1998)
	JS	Povey <i>et al.</i> , "Enhanced Retroviral Transduction of 5-Fluorouracil-Resistant Human Bone Marrow (Stem) Cells Using a Genetically Modified Packaging Cell Line", <i>Blood</i> , <u>92</u> (11):4080-4089 (1998)
	JT	Prasad <i>et al.</i> , "Adeno-associated virus vector mediated gene transfer to pancreatic beta cells," <i>Gene Therapy</i> , <u>7</u> : 1553-1561 (2000)
	JU	Prud'homme and Piccirillo, "The inhibitory effects of transforming growth factor-beta-1 (TGF- $\beta$ 1) in autoimmune diseases," <i>Journal of Autoimmunity</i> , <u>14</u> : 23-42 (2000)
	JV	Ragot <i>et al.</i> , "Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of <i>mdx</i> mice", <i>Nature</i> , <u>361</u> :647-650 (1993)
	JW	Rawls <i>et al.</i> , "Requirements for the mitochondrial import and localization of dihydroorotate dehydrogenase," <i>Eur. J Biochem</i> , <u>267</u> : 2079-2087 (2000)
	JX	Readhead <i>et al.</i> , "Expression of a Myelin Basic Protein Gene in Transgenic Shiverer Mice: Correction of the Dysmyelinating Phenotype", <i>Cell</i> , <u>48</u> :703-712 (1987)
	JY	Remy <i>et al.</i> , "Gene Transfer with a Series of Lipophilic DNA-Binding Molecules", <i>Bioconjug. Chem.</i> , <u>5</u> :647-654 (1994)
	JZ	Riddell <i>et al.</i> , "Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones", <i>Science</i> , <u>257</u> :238-241 (1992)
	KA	Roberts <i>et al.</i> , "Targeting of Human Immunodeficiency Virus-Infected Cells by CD8 T Lymphocytes Armed With Universal T-Cell Receptors", <i>Blood</i> , <u>84</u> (9):2878-2889 (1994)
43	KB	Rooney <i>et al.</i> , "Infusion of cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus-Induced Lymphoma in Allogeneic Transplant Recipients", <i>Blood</i> , <u>92</u> (5):1549-1555 (1998)

EXAMINER

DATE CONSIDERED

2.20.03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24751-2502SERIAL NO.  
09/846,637LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Jensen, Michael C.FILING DATE  
April 30, 2001GROUP  
1632

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

40	KC	Rooney <i>et al.</i> , "Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation", <i>Lancet</i> , <u>345</u> :9-13 (1995)
	KD	Roux <i>et al.</i> , "A versatile and potentially general approach to the targeting of specific cell types by retroviruses: Application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses", <i>Proc. Natl. Acad. Sci. USA</i> , <u>86</u> :9079-9083 (1989)
	KE	Ruckemann <i>et al.</i> , "Leflunomide inhibits pyrimidine <i>de novo</i> synthesis in mitogen-stimulated T lymphocytes from healthy humans," <i>J Bio Chem</i> , <u>273</u> (34): 21682-21691 (1998)
	KF	Sanford <i>et al.</i> , "General Protocol for Microcell-Mediated Chromosome Transfer", <i>Somatic Cell Mol. Genet.</i> , <u>13</u> (3):279-284 (1987)
	KG	Sasaki <i>et al.</i> , "Direct evidence of autosomal recessive inheritance of Arg24 to termination codon in purine nucleoside phosphorylase gene in a family with a severe combined immunodeficiency patient," <i>Hum Genet</i> , <u>103</u> : 81-85 (1998)
	KH	Schaaper, "Mechanisms of mutagenesis in the <i>Escherichia coli</i> mutator <i>mutD5</i> : Role of DNA mismatch repair", <i>Proc. Natl. Acad. Sci. USA</i> , <u>85</u> :8126-8130 (1988)
	KI	Senda and Natsumeda, "Tissue-differentiated expression of two distinct genes for human IMP dehydrogenase (E.C.1.1.1.205)," <i>Life Sciences</i> , <u>54</u> (24): 1917-1926 (1994)
	KJ	Serrano <i>et al.</i> , "Abstract No. 424: A Novel Drug Selection System for Isolating Genetically Modified Human T Lymphocytes Utilizing A Minimally Manipulated Human Type II Inosine Monophosphate Dehydrogenase," <i>The Fourth Annual Meeting of the American Society of Gene Therapy (ASGT) Seattle, Washington, May 30-June 3, 2001</i> <a href="http://www.apnet.com/www/journal/asgt/12103.html">http://www.apnet.com/www/journal/asgt/12103.html</a> (05/01/01)
	KK	Shafer <i>et al.</i> , "Expression of a swine class II gene in murine bone marrow hematopoietic cells by retroviral-mediated gene transfer", <i>Immunol.</i> , <u>88</u> :9760-9765 (1991)
	KL	Shani, "Tissue-specific expression of rat myosin light-chain 2 gene in transgenic mice", <i>Nature</i> , <u>314</u> :283-286 (1985)
	KM	Shaw <i>et al.</i> , "Therapeutic monitoring of mycophenolic acid a consensus panel report," <i>Clinical Biochemistry</i> , <u>31</u> (5): 317-322 (1998)
	KN	Shimada, "Current status and future prospects of human gene therapy," <i>Acta Oaediatica Japonica</i> , <u>38</u> : 176-181 (1996)
40	KO	Sievers <i>et al.</i> , "Mycophenolate Mofetil", <i>Pharmacotherapy</i> , <u>17</u> (6):1178-1197 (1997)

EXAMINER

DATE CONSIDERED

2-20-03

EXAMINER: Initial of citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**

FORM PTO-1449 (Modified)  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 24751-2502	SERIAL NO. 09/846,637
	APPLICANT Jensen, Michael C.	
	FILING DATE April 30, 2001	GROUP 1632

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

40	KP	Silva <i>et al.</i> , "In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis," <i>Transplantation Proceedings</i> , <u>29</u> : 1292-1293 (1997)
	KQ	Silverman Kitchin <i>et al.</i> , "Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses," <i>J Amer Acad Dermatol</i> , <u>37(3)</u> : 445-449 (1997)
	KR	Singhal <i>et al.</i> , "Increased Deoxycytidine Kinase Activity in Cancer Cells and Inhibition by Difluorodeoxycytidine", <i>Oncology Res.</i> , <u>4(11-12)</u> :517-522 (1992)
	KS	<del>Soilu-Hanninen <i>et al.</i>, "Treatment of experimental autoimmune encephalomyelitis with antisense oligonucleotides against the low affinity neurotrophin receptor," <i>J Neuroscience Research</i>, <u>59</u>: 712-721 (2000)</del>
	KT	Sokol and Gewirtz, "Gene therapy: basic concepts and recent advances," <i>Crit. Reviews Eukaryotic Gene Expression</i> , <u>6(1)</u> : 29-57 (1996)
	KU	Sollinger <i>et al.</i> , "RS-61443—A Phase I Clinical Trail and Pilot Rescue Study", <i>Transplantation</i> , <u>53(2)</u> :428-432 (1992)
	KV	Stepkowski, S., "Molecular targets for existing and novel immunosuppressive drugs," <i>Expert Reviews in Molecular Medicine</i> , 1-23 (2000)
	KW	Strauss, "Transfection of Mammalian Cells via Lipofection", <i>Meth. Mol. Biol.</i> , <u>54</u> :307-327 (1996)
	KX	Stroncek <i>et al.</i> , "Retroviral transduction and expansion of peripheral blood lymphocytes for the treatment of mucopolysaccharidosis type II, Hunter's syndrome," <i>Transfusion</i> , <u>39</u> : 343-350 (1999)
	KY	Swift <i>et al.</i> , "Tissue-Specific Expression of the Rat Pancreatic Elastase I Gene in Transgenic Mice", <i>Cell</i> , <u>38</u> :639-646 (1984)
	KZ	Szekeres <i>et al.</i> , "Synergistische zytotoxische effekte einer chemotherapie an kolontumorzellen durch gleichzeitige hemmung von de novo und salvage stoffwechselwegen," <i>Wien Klin Wochenschr.</i> , <u>106(14)</u> : 459-463 (1994)
	LA	Takebe <i>et al.</i> , "SR $\alpha$ Promoter: an Efficient and Versatile Mammalian cDNA Expression System Composed of the Simian Virus 40 Early Promoter and the R-U5 Segment of Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat", <i>Mol. Cell. Biol.</i> , <u>8(1)</u> :466-472 (1988)
	LB	Takiguchi <i>et al.</i> , "CTLA41gG gene delivery prevents autoantibody production and lupus nephritis in MRL/lpr MICE," <i>Life Sciences</i> , <u>66(11)</u> : 991-1001 (2000)
40	LC	Teifel <i>et al.</i> , "New Lipid Mixture for Efficient Lipid-Mediated Transfection of BHK Cells", <i>Biotechniques</i> , <u>19</u> :79-80 (1995)

EXAMINER

DATE CONSIDERED 2.20.03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24751-2502	SERIAL NO. 09/846,637
	APPLICANT Jensen, Michael C.	
	FILING DATE April 30, 2001	GROUP 1632

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

ygg	LD	The Mycophenolate Mofetil Renal Refractory Rejection Study Group, "Mycophenolate Mofetil for the Treatment of Refractory, Acute, Cellular Renal Transplant Rejection", <i>Transplantation</i> , <u>61</u> :722-729 (1996)
	LE	Tillotson <i>et al.</i> , "Inhibition of thymidine kinase in cultured mammary tumor cells by the chemopreventive organoselenium compound, 1,4-phenylenebis(methylene)selenocyanate", <i>Carcinogenesis</i> , <u>15</u> (4):607-610 (1994)
	LF	Tomita <i>et al.</i> , "Direct in Vivo Gene Introduction Into Rat Kidney", <i>Biochem. Biophys. Res. Commun.</i> , <u>186</u> :129-134 (1992)
	LG	Tran <i>et al.</i> , "Chimeric $\zeta$ -Receptors Direct Human Natural Killer (NK) Effector Function to Permit Killing of NK-Resistant Tumor Cells and HIV-Infected T Lymphocytes", <i>J. Immunol.</i> , <u>155</u> :1000-1009 (1994)
	LH	Treisman <i>et al.</i> , "Upregulation of Tumor Necrosis Factor- $\alpha$ Production by Retrovirally Transduced Human Tumor-Infiltrating Lymphocytes Using <i>trans</i> -Retinoic Acid", <i>Cell Immunol.</i> , <u>156</u> :448-457 (1994)
	LI	Tricot and Weber, "Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity*", <i>Anticancer Research</i> , <u>16</u> : 3341-3348 (1996)
	LJ	Tsukamoto <i>et al.</i> , "Inhibition of Thymidylate Synthase and Thymidine Kinase by Okadaic Acid in Regenerating rat Liver after Partial Hepatectomy", <i>Biochem. Pharmacol.</i> , <u>52</u> :879-884 (1996)
	LK	Tsui <i>et al.</i> , "Program No. 551: Chimeric p27-p16 Gene Therapy Inhibits Balloon Injury-induced Neointimal Hyperplasia in Cholesterol-fed Rabbits," <i>The Third Annual Meeting of the American Society of Gene Therapy (ASGT) Denver, Colorado, May 31- June 4, 2000</i> <a href="http://www/apnet.com/www/journal/asgt/8807.html">http://www/apnet.com/www/journal/asgt/8807.html</a> (12/26/00)
	LL	Tuohy and Mathisen, "T cell design for therapy in autoimmune demyelinating disease," <i>J Neuroimmunology</i> , <u>107</u> : 226-232 (2000)
	LM	Van Bruggen <i>et al.</i> , "Attenuation of murine lupus nephritis by mycophenolate mofetil," <i>J Am Soc Nephrol</i> , <u>9</u> : 1407-1415 (1998)
	LN	Vandevyver <i>et al.</i> , "Clonal expansion of myelin basic protein-reactive T cells in patients with multiple sclerosis: restricted T cell receptor V gene rearrangements and CDR3 sequence", <i>Eur. J. Immunol.</i> , <u>25</u> (4):958-968 (1995)
ygl	LO	Villa-Komaroff <i>et al.</i> , "A bacterial clone synthesizing proinsulin", <i>Proc. Natl. Acad. Sci. USA</i> , <u>75</u> (8):3727-3731 (1978)

EXAMINER

ygh

DATE CONSIDERED

2.20.03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24751-2502	SERIAL NO. 09/846,637
	APPLICANT Jensen, Michael C.	
	FILING DATE April 30, 2001	GROUP 1632
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

y89	LP	Voeller <i>et al.</i> , "Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs", <i>Cancer Chemotherapy Pharmacol.</i> , <u>45(5)</u> :409-416 (2000)
	LQ	Wagner <i>et al.</i> , "Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1", <i>Proc. Natl. Acad. Sci. USA</i> , <u>78(3)</u> :1441-1445 (1981)
	LR	Waldman <i>et al.</i> , "Inhibition of Cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide," <u>42</u> : 412-418 (1999)
	LS	Walter <i>et al.</i> , "Reconstitution of Cellular Immunity Against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-cell Clones from the Donor", <i>N. Engl. J. Med.</i> , <u>333</u> :1038-1044 (1995)
	LT	Wang and Hedstrom, "Kinetic mechanism of Human Inosine 5'-Monophosphate Dehydrogenase Type II: Random Addition of Substrates and Ordered Release of Products", <i>Biochem.</i> , <u>36</u> :8479-8473 (1997)
	LU	Wardle, E.N., "Glomerulonephritis," <i>Lancet</i> , <u>354</u> : 428-429 (1999)
	LV	Weber <i>et al.</i> , "Regulation of <i>De Novo</i> and Salvage Pathways in Chemotherapy", <i>Adv. Enzyme. Regul.</i> , <u>31</u> :45-67 (1991)
	LW	Wigler <i>et al.</i> , "DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells", <i>Proc. Natl. Acad. Sci. USA</i> , <u>76(3)</u> :1373-1376 (1979)
	LX	Williams <i>et al.</i> , "Leflunomide in Experimental Transplantation", <i>Transplantation</i> , <u>57(8)</u> :1223-1231 (1994)
	LY	Wilson <i>et al.</i> , "Correction of CD18-Deficient lymphocytes by retrovirus-mediated gene transfer," <i>Science</i> , <u>248</u> : 1413-1416 (1990)
	LZ	Wintersperger <i>et al.</i> , "A transient assay for gene expression studies in B lymphocytes and its use for superantigen assays," <i>BioTechniques</i> , <u>16(5)</u> : 882-886 (1994)
	MA	Woffendin <i>et al.</i> , "Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells", <i>Proc. Natl. Acad. Sci. USA</i> , <u>91</u> :11581-11585 (1994)
	MB	Wolff <i>et al.</i> , "Direct Gene Transfer into Mouse Muscle in Vivo", <i>Science</i> , <u>247</u> :1465-1468 (1990)
y88	MC	Woo <i>et al.</i> , "The antilymphocytic activity of brequinar sodium and its potentiation by cytidine," <i>Transplantation</i> , <u>56(2)</u> : 374-381 (1993)

EXAMINER

y88

DATE CONSIDERED

2.20.03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24751-2502SERIAL NO.  
09/846,637LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Jensen, Michael C.FILING DATE  
April 30, 2001GROUP  
1632

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

48	MD	Wu, J., "Mycophenolate mofetil: Molecular mechanisms of action", <i>Perspect. Drug Discovery Des.</i> , <u>2</u> :185-204 (1994)
	ME	Xu <i>et al.</i> , "Control of lymphoproliferative and autoimmune disease in MRL- <i>lpr/lpr</i> mice by brequinar sodium: mechanisms of action," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , <u>283</u> (2): 869-875 (1997)
	MF	Xu <i>et al.</i> , "In Vitro and In Vivo Mechanisms of Action of the Antiproliferative and Immunosuppressive Agent, Brequinar Sodium", <i>J. Immun.</i> , <u>160</u> :846-853 (1998)
	MG	Xu <i>et al.</i> , "Two activities of the immunosuppressive metabolite of leflunomide, A77 1726," <i>Biochemical Pharmacology</i> , <u>52</u> : 527-534 (1996)
	MH	Yalowitz and Jayaram, "Molecular Targets of Guanine Nucleotides in Differentiation, Proliferation and Apoptosis", <i>Anticancer Res.</i> , <u>20</u> :2329-2338 (2000)
	MI	Yamada <i>et al.</i> , "Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1", <i>Gene Ther.</i> , <u>1</u> :38-45 (1994)
	MJ	Yamada <i>et al.</i> , "IMP Dehydrogenase: Inhibition by the Anti-Leukemic Drug, Tiazofurin", <i>Leuk. Res.</i> , <u>13</u> (2):179-184 (1989)
	MK	Yamamoto <i>et al.</i> , "Identification of a Functional Promoter in the Long Terminal Repeat of Rous Sarcoma Virus", <i>Cell</i> , <u>22</u> :787-797 (1980)
	ML	Yang <i>et al.</i> , "In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment", <i>Proc. Natl. Acad. Sci. USA</i> , <u>87</u> :9568-9572 (1990)
	MM	Yokoo and Kitamura, "Gene transfer of interleukin-1 receptor antagonist into the renal glomerulus via a mesangial cell vector," <i>Biochem Biophys Res Commun.</i> , <u>226</u> : 883-888 (1996)
	MN	Yu <i>et al.</i> , "Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against human immunodeficiency virus type 1", <i>Proc. Natl. Acad. Sci. USA</i> , <u>92</u> :699-703 (1995)
	MO	Zambidis <i>et al.</i> , "Genetically Transferred Central and Peripheral Immune Tolerance via Retroviral-Mediated Expression of Immunogenic Epitopes in Hematopoietic Progenitors or Peripheral B Lymphocytes", <i>Mol. Med.</i> , <u>3</u> (3):212-224 (1997)
	MP	Zhang <i>et al.</i> , "Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells", <i>Nat. Biotechnol.</i> , <u>16</u> :1045-1049 (1998)
49	MQ	Zhang <i>et al.</i> , "Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice", <i>J. Clin. Invest.</i> , <u>105</u> (6):813-821 (2000)

EXAMINER

Yonah

DATE CONSIDERED

2.20.03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**



FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24751-2502SERIAL NO.  
09/846,637LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Jensen, Michael C.FILING DATE  
April 30, 2001GROUP  
1632

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

YJ	MR	Zhou <i>et al.</i> , "Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti- <i>tat</i> and <i>rev</i> hammerhead ribozymes", <i>Gene</i> , <u>149</u> :33-39 (1994)
YJ	MS	Zhu <i>et al.</i> , "Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice", <i>Science</i> , <u>261</u> :209-211 (1993)
YJ	MT	Zimmerman <i>et al.</i> , "Regulation of inosine-5'-monophosphate dehydrogenase type II gene expression in human T cells," <i>J Biol Chem</i> , <u>272</u> (36): 22913-22923 (1997)
YJ	MU	Ziswiler <i>et al.</i> , "Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis," <i>J Am Soc Nephrol</i> , <u>9</u> : 2055-2066 (1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **SELECTION SYSTEMS FOR GENETICALLY MODIFIED CELLS**